MY186477A - Dry coated tablet - Google Patents
Dry coated tabletInfo
- Publication number
- MY186477A MY186477A MYPI2014701426A MYPI2014701426A MY186477A MY 186477 A MY186477 A MY 186477A MY PI2014701426 A MYPI2014701426 A MY PI2014701426A MY PI2014701426 A MYPI2014701426 A MY PI2014701426A MY 186477 A MY186477 A MY 186477A
- Authority
- MY
- Malaysia
- Prior art keywords
- coated tablet
- dry coated
- active ingredient
- outer layer
- inner core
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Sampling And Sample Adjustment (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011262679 | 2011-11-30 | ||
| PCT/JP2012/081583 WO2013081177A1 (en) | 2011-11-30 | 2012-11-29 | Dry coated tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY186477A true MY186477A (en) | 2021-07-22 |
Family
ID=47428946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2014701426A MY186477A (en) | 2011-11-30 | 2012-11-29 | Dry coated tablet |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9433632B2 (enExample) |
| EP (1) | EP2785331B1 (enExample) |
| JP (1) | JP5925318B2 (enExample) |
| KR (1) | KR101952478B1 (enExample) |
| CN (1) | CN104080446B (enExample) |
| AR (1) | AR089032A1 (enExample) |
| CA (1) | CA2857457C (enExample) |
| ES (1) | ES2561098T3 (enExample) |
| MY (1) | MY186477A (enExample) |
| PH (1) | PH12014501218B1 (enExample) |
| SG (1) | SG11201402400YA (enExample) |
| TW (1) | TWI630002B (enExample) |
| UY (1) | UY34478A (enExample) |
| WO (1) | WO2013081177A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9693962B2 (en) | 2012-06-05 | 2017-07-04 | Takeda Pharmaceutical Limited | Dry-coated tablet |
| SG11201509439SA (en) | 2013-05-21 | 2015-12-30 | Takeda Pharmaceutical | Orally disintegrable tablet |
| ES2806426T3 (es) * | 2014-10-08 | 2021-02-17 | Synthetic Biologics Inc | Formulaciones de betalactamasas y usos de las mismas |
| CR20180119A (es) | 2015-07-30 | 2018-03-21 | Takeda Pharmaceuticals Co | Tableta |
| WO2018195205A1 (en) * | 2017-04-18 | 2018-10-25 | Sensient Colors Llc | Dosage form coating composition and method of making and using the same |
| KR20230079457A (ko) * | 2017-12-29 | 2023-06-07 | 락손 메디칼 아게 | 약물 전달 시스템 |
| KR20190092805A (ko) | 2018-01-31 | 2019-08-08 | 삼진제약주식회사 | 아세틸살리실산 및 란소프라졸을 포함하는 약학적 조성물 |
| WO2022049310A1 (en) * | 2020-09-07 | 2022-03-10 | Cyprumed Gmbh | Improved pharmaceutical formulations of glp-1 receptor agonists |
| EP4091605A1 (en) | 2021-05-19 | 2022-11-23 | G.L. Pharma GmbH | Pharmaceutical tablet comprising acetylsalicylic acid |
| KR20230149188A (ko) | 2022-04-19 | 2023-10-26 | 한미약품 주식회사 | 아세틸살리실산 및 프로톤 펌프 저해제를 포함하는 약학적 조성물 |
| WO2023204397A1 (ko) | 2022-04-19 | 2023-10-26 | 한미약품 주식회사 | 아세틸살리실산 및 프로톤 펌프 저해제를 포함하는 약학적 조성물 |
| KR20240043707A (ko) | 2022-09-27 | 2024-04-03 | 한미약품 주식회사 | 아세틸살리실산 및 프로톤 펌프 저해제를 포함하는 약학적 조성물 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| JPH072761B2 (ja) | 1985-03-20 | 1995-01-18 | 不二パウダル株式会社 | 微結晶セルロ−ス球形顆粒及びその製造法 |
| JP2820829B2 (ja) | 1991-03-07 | 1998-11-05 | 武田薬品工業株式会社 | 有核散剤およびその製造方法 |
| JPH04346930A (ja) | 1991-05-25 | 1992-12-02 | Sumitomo Pharmaceut Co Ltd | 安定なアスピリン腸溶錠 |
| SE9600070D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| TW385306B (en) | 1996-11-14 | 2000-03-21 | Takeda Chemical Industries Ltd | Method for producing crystals of benzimidazole derivatives |
| JP3828648B2 (ja) | 1996-11-14 | 2006-10-04 | 武田薬品工業株式会社 | ２−（２−ピリジルメチルスルフィニル）ベンズイミダゾール系化合物の結晶およびその製造法 |
| US6235311B1 (en) * | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
| KR100554924B1 (ko) * | 1998-05-18 | 2006-03-03 | 다케다 야쿠힌 고교 가부시키가이샤 | 구강내 붕괴 정제 |
| CA2338792C (en) | 1998-07-28 | 2006-01-17 | Takeda Chemical Industries, Ltd. | Rapidly disintegrable solid preparation |
| TWI275587B (en) | 1999-06-17 | 2007-03-11 | Takeda Chemical Industries Ltd | A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
| CA2407208C (en) | 2000-04-28 | 2010-08-17 | Takeda Chemical Industries, Ltd. | Process for producing optically active sulfoxide derivative |
| AU2001256732A1 (en) | 2000-05-15 | 2001-11-26 | Takeda Chemical Industries Ltd. | Process for producing crystal |
| PL214684B1 (pl) | 2000-12-01 | 2013-09-30 | Takeda Pharmaceutical | Sposób wytwarzania krysztalów (R) lub (S)-2-[[[3-metylo-4-(2,2,2-trifluoroetoksy)-2-pirydynylo]metylo]sulfinylo]-1H-benzimidazolu |
| PT1411900E (pt) | 2001-06-01 | 2010-10-11 | Pozen Inc | Composições farmacêuticas para a entrega coordenada de aines |
| US8206741B2 (en) * | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| WO2005076987A2 (en) | 2004-02-10 | 2005-08-25 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent |
| US20080166407A1 (en) * | 2005-07-29 | 2008-07-10 | Shalaby Shalaby W | Solid oral formulations for combination therapy |
| DE102005047616A1 (de) * | 2005-10-05 | 2007-05-31 | Bayer Healthcare Ag | Kombination |
| AR057181A1 (es) | 2005-11-30 | 2007-11-21 | Astra Ab | Nueva forma de dosificacion de combinacion |
| JP5529404B2 (ja) | 2008-09-05 | 2014-06-25 | 東和薬品株式会社 | アスピリン腸溶錠 |
| JP2012531430A (ja) * | 2009-06-25 | 2012-12-10 | ポーゼン インコーポレイテッド | アスピリン療法を必要とする患者を治療するための方法 |
| WO2011144994A1 (en) * | 2010-05-21 | 2011-11-24 | Lupin Limited | Pharmaceutical compositions of nsaid and acid inhibitor |
| SG190717A1 (en) * | 2010-12-03 | 2013-07-31 | Takeda Pharmaceutical | Orally disintegrating tablet |
-
2012
- 2012-11-29 WO PCT/JP2012/081583 patent/WO2013081177A1/en not_active Ceased
- 2012-11-29 TW TW101144687A patent/TWI630002B/zh not_active IP Right Cessation
- 2012-11-29 CN CN201280067760.3A patent/CN104080446B/zh not_active Expired - Fee Related
- 2012-11-29 UY UY0001034478A patent/UY34478A/es not_active Application Discontinuation
- 2012-11-29 US US14/361,554 patent/US9433632B2/en not_active Expired - Fee Related
- 2012-11-29 MY MYPI2014701426A patent/MY186477A/en unknown
- 2012-11-29 AR ARP120104489A patent/AR089032A1/es not_active Application Discontinuation
- 2012-11-29 CA CA2857457A patent/CA2857457C/en not_active Expired - Fee Related
- 2012-11-29 SG SG11201402400YA patent/SG11201402400YA/en unknown
- 2012-11-29 ES ES12805787.4T patent/ES2561098T3/es active Active
- 2012-11-29 EP EP12805787.4A patent/EP2785331B1/en not_active Not-in-force
- 2012-11-29 JP JP2014525239A patent/JP5925318B2/ja active Active
- 2012-11-29 KR KR1020147017678A patent/KR101952478B1/ko not_active Expired - Fee Related
-
2014
- 2014-05-29 PH PH12014501218A patent/PH12014501218B1/en unknown
-
2016
- 2016-08-02 US US15/226,612 patent/US10238605B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| TWI630002B (zh) | 2018-07-21 |
| PH12014501218A1 (en) | 2014-09-08 |
| PH12014501218B1 (en) | 2014-09-08 |
| HK1197581A1 (zh) | 2015-01-30 |
| KR20140096157A (ko) | 2014-08-04 |
| EP2785331A1 (en) | 2014-10-08 |
| CN104080446B (zh) | 2018-06-29 |
| US20140335181A1 (en) | 2014-11-13 |
| CA2857457A1 (en) | 2013-06-06 |
| US10238605B2 (en) | 2019-03-26 |
| ES2561098T3 (es) | 2016-02-24 |
| UY34478A (es) | 2013-06-28 |
| US20170014347A1 (en) | 2017-01-19 |
| TW201328726A (zh) | 2013-07-16 |
| SG11201402400YA (en) | 2014-06-27 |
| WO2013081177A1 (en) | 2013-06-06 |
| CA2857457C (en) | 2018-05-01 |
| KR101952478B1 (ko) | 2019-02-26 |
| US9433632B2 (en) | 2016-09-06 |
| JP2014533656A (ja) | 2014-12-15 |
| EP2785331B1 (en) | 2015-11-18 |
| JP5925318B2 (ja) | 2016-05-25 |
| CN104080446A (zh) | 2014-10-01 |
| AR089032A1 (es) | 2014-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY186477A (en) | Dry coated tablet | |
| CR20130287A (es) | Tableta oralmente desintegradora | |
| MY184077A (en) | Orally disintegrable tablet | |
| MY189306A (en) | Tablet | |
| PH12016500121A1 (en) | Pharmaceutical tablet comprising acetylsalicyclic acid and clopidogrel | |
| CR20140485A (es) | Formulacion de farmaco de liberacion retardada | |
| MX393588B (es) | Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usos | |
| ECSP13012825A (es) | Tableta oralmente desintegradora | |
| CR20160192A (es) | Formulación de farmaco de liberación retardada | |
| IN2015DN04161A (enExample) | ||
| PH12014502609A1 (en) | Mutilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug | |
| BR112014019526B8 (pt) | Forma de dosagem de liberação rápida e seu método de produção | |
| EP2452678A3 (en) | Pulsatile-release pharmaceutical formulation of dexlansoprazole | |
| WO2012127495A3 (en) | Pharmaceutical composition and process for preparation thereof | |
| SA517380942B1 (ar) | صيغة إطلاق متعددة النماذج للدوكسيلامين والبيريدوكسين و/أو نواتج أيض أو أملاح منها | |
| MX2015006356A (es) | Formulacion de capsula de acido 5-aminosalicilico. | |
| TH153153A (th) | ยาเม็ดเคลือบแห้ง | |
| UA59388U (ru) | Комбинированный лекарственный препарат анальгетического, противовоспалительного и жаропонижающего действия | |
| NZ628867A (en) | Pharmaceutical formulation containing flupirtine | |
| TH169516A (th) | ยาเม็ดชนิดแตกตัวได้ในช่องปาก |